Skip to content
Assyro AI
US FDA source recordWL · Warning Letter

Genzyme Ireland Limited — FDA Warning Letter

Issued to Genzyme Ireland Limited. Serious post-market compliance violation.

Issued

June 22, 2026

Product

CGMP/Deviations/Biologics License Application (BLA)

Company

Genzyme Ireland Limited

Review center

CBER

Stage

Final Decision

Read source documentView similar WL records

Assyro regulatory brief

Free

Why did Genzyme Ireland Limited receive an FDA warning letter?

Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.

Verify in source

Source facts

FDA issued a warning letter to Genzyme Ireland Limited concerning CGMP/Deviations/Biologics License Application (BLA). Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

Key details in this letter

  • 1Subject: CGMP/Deviations/Biologics License Application (BLA).
  • 2Issuing office: Center for Biologics Evaluation and Research (CBER).
  • 3Manufacturing and CGMP controls: 1 source-text match.
  • 4No closeout letter was listed in the source metadata at refresh time.
Manufacturing and CGMP controls

Suggested next step

Review the exact FDA warning letter, cited violations, requested corrections, and any later response or closeout before assessing current status.

Open the document workspace

Built from structured FDA metadata and deterministic source-text signals. Topic matches are navigation aids, not legal or regulatory conclusions. Verify material decisions against the original FDA document.

FDAHTMLUpdated Jul 30, 2026

FDA source document

Read the full FDA warning letter

FDA publishes this warning letter as a web document.

Open the exact FDA source to read the complete letter and verify its current response or closeout status.

Open source on FDA.gov

Common questions about the Genzyme Ireland Limited warning letter

What does this warning letter mean for Genzyme Ireland Limited?

Serious post-market compliance violation. Public notice requiring prompt remediation. FDA issued this letter on June 22, 2026.

What happens after an FDA warning letter?

The firm is expected to respond in writing, normally within 15 working days, describing corrective actions and timelines. FDA verifies remediation — often through reinspection — and issues a closeout letter when violations are corrected. Unresolved warning letters can escalate to import alerts, seizure, or injunction.